(Q36543116)

14 August 2017

1 reference

title

The road map to oral bioavailability: an industrial perspective (English)

1 reference

14 August 2017

1 reference

V Hayden Thomas

1

1 reference

14 August 2017

Shobha Bhattachar

2

1 reference

14 August 2017

Linda Hitchingham

3

1 reference

14 August 2017

Philip Zocharski

4

1 reference

14 August 2017

Maryanne Naath

5

1 reference

14 August 2017

Narayanan Surendran

6

1 reference

14 August 2017

Chad L Stoner

7

1 reference

14 August 2017

Ayman El-Kattan

8

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Expert Opinion on Drug Metabolism & Toxicology

14 August 2017

1 reference

14 August 2017

2

1 reference

14 August 2017

591-608

1 reference

14 August 2017

4

1 reference

The price of innovation: new estimates of drug development costs

14 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

High-throughput drug discovery: what can we expect from HTS?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Property-based design: optimization of drug absorption and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Profiling drug-like properties in discovery research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

High throughput physicochemical profiling for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Physicochemical profiling in drug research: a brief survey of the state-of-the-art of experimental techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Drug-like properties and the causes of poor solubility and poor permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Polar molecular surface properties predict the intestinal absorption of drugs in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Automated robotic liquid handling/laser-based nephelometry system for high throughput measurement of kinetic aqueous solubility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Estimation of the aqueous solubility I: application to organic nonelectrolytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Design and synthesis of novel quinoxaline-2,3-dione AMPA/GlyN receptor antagonists: amino acid derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

pH–Solubility Profiles of Organic Carboxylic Acids and Their Salts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Solubility of organic hydrochlorides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

IV-IVC considerations in the development of immediate-release oral dosage form

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

The mean dissolution time depends on the dose/solubility ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Pyrroloquinolone PDE5 inhibitors with improved pharmaceutical profiles for clinical studies on erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Guidance in the setting of drug particle size specifications to minimize variability in absorption.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Particle size distribution affects the human bioavailability of phenytoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Membrane transport of drugs in different regions of the intestinal tract of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Drug delivery to the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Intestinal absorption of drugs mediated by drug transporters: mechanisms and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Improved intestinal transport of PD 158473, an N-methyl-D-aspartate (NMDA) antagonist, by involvement of multiple transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds--implications for pharmacokinetics of selected substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Effects of ketoconazole on digoxin absorption and disposition in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Classification analysis of P-glycoprotein substrate specificity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Structure-activity relationship of P-glycoprotein substrates and modifiers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

The medicinal chemistry of multidrug resistance (MDR) reversing drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Increasing the throughput and productivity of Caco-2 cell permeability assays using liquid chromatography-mass spectrometry: application to resveratrol absorption and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Human intestinal permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Estimating human drug oral absorption kinetics from Caco-2 permeability using an absorption-disposition model: model development and evaluation and derivation of analytical solutions for k(a) and F(a).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Acid-base cosolvent method for determining aqueous permeability of amiodarone, itraconazole, tamoxifen, terfenadine and other very insoluble molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Synthesis and biological evaluation of imidazole-based small molecule antagonists of the melanocortin 4 receptor (MC4-R).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Impact of drug transporter studies on drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Drug-metabolizing enzymes: mechanisms and functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

The roles of transporters and enzymes in hepatic drug processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

How important are gender differences in pharmacokinetics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Liver function and phase I drug metabolism in the elderly: a paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Induction of phase I, II and III drug metabolism/transport by xenobiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Cancer and phase II drug-metabolizing enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Use of cloned and expressed human liver UDP-glucuronosyltransferases for analysis of drug glucuronide formation and assessment of drug toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Characterization of molecular species of liver microsomal carboxylesterases of several animal species and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Comparison of the disposition and of the metabolic pattern of Reboxetine, a new antidepressant, in the rat, dog, monkey and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Substrate SARs in human P450s

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

The impact of lipophilicity in drug research: a case report on beta-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Pharmacokinetics of selective estrogen receptor modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Suitability of animal models for predictive toxicology: theoretical and practical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

Predicting Drug Metabolism: A Site of Metabolism Prediction Tool Applied to the Cytochrome P450 2C9

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2.4.591

21 January 2018

Identifiers

DOI

10.1517/17425255.2.4.591

1 reference

14 August 2017

1 reference